Team
The team of experienced biotech specialists has established an enviable track record in identifying and managing investment opportunities in the biotech sector.

Dr. Daniel Koller
Head Investment Management
Dr. Daniel Koller
Head Investment Management
Felicia Flanigan
Investment Management Team
Felicia Flanigan
Investment Management Team
Dallas Webb
Investment Management Team
Dallas Webb
Investment Management Team
Dr. Christian Koch
Investment Management Team
Dr. Christian Koch
Investment Management TeamIts academic expertise, many years of experience and collaboration, and a broad interest in all areas of medicine, biochemistry, and economics ensure an inspiring and constructive interdisciplinary dialogue within the team and with the Board of Directors as well as with external experts such as physicians and analysts.

Dr. Stephen Taubenfeld
Investment Management Team
Dr. Stephen Taubenfeld
Investment Management Team
Dr. Maurizio Bernasconi
Investment Management Team
Dr. Maurizio Bernasconi
Investment Management Team
Dr. Samuel Croset
Investment Management Team
Dr. Samuel Croset
Investment Management TeamDr. Samuel Croset joined Bellevue Asset Management as a Portfolio Manager and Digital Transformation Lead in 2020. He previously worked for Roivant Sciences from 2018-2020 as data scientist supporting investment decisions in drug projects as well as leading a team focused on the analysis of real-world data. Prior to that, he started his professional career at Roche as data scientist in the research department (2014-2018). Samuel holds a Ph.D. in Bioinformatics from the University of Cambridge, a MS in Bioinformatics and a MS in Biochemistry from the University of Geneva.

Dr. Silvia Siegfried-Schanz
Investor Relations
Dr. Silvia Siegfried-Schanz
Investor Relations- Since 2012 with Bellevue Asset Management as Director Investor Relations for the investment company BB Biotech AG
- 2011 – 2012 UBS Wealth Management, Buy-side Financial Analyst, Global Healthcare
- 2008 – 2011 Vontobel Investment Banking, Sell-side Financial Analyst, Pharmaceuticals and Biotechnology
- Certified International Investment Analyst (CIIA)
- PhD / doctorate in Biochemistry of the Swiss Federal Institute of Technology (ETH) Zurich
- Master in Biochemistry, minor in Business Administration of the University Freiburg

Claude Mikkelsen
Investor Relations
Claude Mikkelsen
Investor Relations- Since 2012 with Bellevue Asset Management as Director Investor Relations for the investment company BB Biotech AG
- 2011-2012 Finance Director (interim), Nordic Region at Ecron Acunova A/S
- 2009-2012 Senior Consultant, CMI Consulting
- 2005-2009 Senior Vice President, Finance & Investor Relations at Pharmexa A/S
- 2003-2005 Legal Consultant at Dako A/S
- 2001-2003 Consultant at Deloitte
- Master’s degree in Economy and Law, Aalborg University

Maria-Grazia Iten-Alderuccio
Investor Relations
Maria-Grazia Iten-Alderuccio
Investor Relations- Since 2007 with Bellevue Asset Management as Director Investor Relations BB Biotech AG
- 2004–2007 Citco Fund Advisors, senior relationship manager
- Master's degree in Linguistics from the University of Lausanne and Università degli Studi di Firenze, Italy